homepage-top-section

HBM7575/SKB575 is designed to target thymic stromal lymphopoietin (TSLP) as well as an undisclosed antigen. The long-acting antibody uses a dual mechanism of action. It works to block

IBI355 is an Fc-silent, third-generation anti-CD40L antibody that is expected to advance to Phase II trials for immunoglobulin G4 (IgG4)-related disease. Spero plans to launch a global Phase

AstraZeneca will obtain a licence to develop, manufacture and commercialise the phosphodiesterase 3/4 (PDE3/4) inhibitor, TQC3721, outside China. The agreement also covers certain future development programmes on an

Under this collaboration, Biocytogen will offer access to up to five bispecific antibodies via its RenLite platform. Whitehawk Therapeutics will assess them in conjunction with its own ADC

The decision is based on data from the pivotal Phase III EPCORE FL-1 trial, which assessed the efficacy and safety of the fixed-duration Tepkinly plus lenalidomide and rituximab

With this decision, Itvisma becomes the only gene replacement therapy which is currently approved for this wider patient population within the EU. Itvisma works by providing a functional

Under this agreement, Innovent will handle the marketing, distribution and promotion of the product within the region, while Eli Lilly will continue to manage manufacturing, supply and development. Verzenios

Under the terms of the deal, Theravance Biopharma shareholders will receive $17 per share. Shareholders will also receive a contingent value right (CVR) entitling them to 80% of

This Jaypirca CHMP recommendation for CLL applies across all lines of therapy, regardless of previous Bruton tyrosine kinase (BTK) inhibitor treatment. Following this recommendation, the Jaypirca application moves